This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shelton, M. J.
Right arrow Articles by Morse, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shelton, M. J.
Right arrow Articles by Morse, G. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2003, p. 1694-1699, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1694-1699.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Ritonavir and Delavirdine in Human Immunodeficiency Virus-Infected Patients

Mark J. Shelton,1 Ross G. Hewitt,1,2 John Adams,1,2 Andrew Della-Coletta,3 Steven Cox,3 and Gene D. Morse1,2*

Laboratory for Antiviral Research, Departments of Pharmacy Practice and Medicine, University at Buffalo,1 Antiviral Clinical Pharmacology Unit, Immunodeficiency Services, Erie County Medical Center, Buffalo, New York,2 Clinical Pharmacokinetics Unit, Pharmacia & Upjohn Company, Kalamazoo, Michigan3

Received 1 March 2002/ Returned for modification 21 June 2002/ Accepted 11 February 2003

To evaluate the pharmacokinetic effect of adding delavirdine mesylate to the antiretroviral regimens of human immunodeficiency virus (HIV)-infected patients stabilized on a full dosage of ritonavir (600 mg every 12 h), 12 HIV-1-infected subjects had delavirdine mesylate (400 mg every 8 h) added to their current antiretroviral regimens for 21 days. Ritonavir pharmacokinetics were evaluated before (day 7) and after (day 28) the addition of delavirdine, and delavirdine pharmacokinetics were evaluated on day 28. The mean values (± standard deviations) for the maximum concentration in serum (Cmax) of ritonavir, the area under the concentration-time curve from 0 to 12 h (AUC0-12), and the minimum concentration in serum (Cmin) of ritonavir before the addition of delavirdine were 14.8 ± 6.7 µM, 94 ± 36 µM · h, and 3.6 ± 2.1 µM, respectively. These same parameters were increased to 24.6 ± 13.9 µM, 154 ± 83 µM · h, and 6.52 ± 4.85 µM, respectively, after the addition of delavirdine (P is <0.05 for all comparisons). Delavirdine pharmacokinetic parameters in the presence of ritonavir included a Cmax of 23 ± 16 µM, an AUC0-8 of 114 ± 75 µM · h, and a Cmin of 9.1 ± 7.5 µM. Therefore, delavirdine increases systemic exposure to ritonavir by 50 to 80% when the drugs are coadministered.

* Corresponding author. Mailing address: 317 Hochstetter Hall, Department of Pharmacy Practice, University at Buffalo, Amherst, NY 14260-1200. Phone: (716) 645-2828, ext 252. Fax: (716) 645-2886. E-mail: emorse{at}.buffalo.edu.

Antimicrobial Agents and Chemotherapy, May 2003, p. 1694-1699, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1694-1699.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Morse, G. D., Rosenkranz, S., Para, M. F., Segal, Y., DiFrancesco, R., Adams, E., Brizz, B., Yarasheski, K. E., Reichman, R. C., the ACTG 5043 Protocol Team, (2005). Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative Individuals. Antimicrob. Agents Chemother. 49: 3373-3381 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»